Structural and Functional Changes in Mild Cognitive Impairment in Parkinson's Disease
Halil Güllüoğlu1, Duygu Hünerli2, Raif Çakmur3
1Department of Neurology, Izmir Ekonomi University Medical Point Hospital, Izmir 35080, Turkey.
Medicina (Kaunas, Lithuania)
|January 23, 2024
Summary
White matter volume loss is more pronounced in Parkinson's disease with mild cognitive impairment (PD-MCI) than gray matter loss. Neuropsychological test impairments correlate with reduced brain volumes in PD-MCI patients.
Area of Science:
- Neurology
- Neuroimaging
- Cognitive Science
Background:
- The exact causes of mild cognitive impairment in Parkinson's disease (PD-MCI) remain unclear.
- Early-stage PD-MCI may involve volume loss in specific brain regions like the occipital, parietal, and frontal cortices, and hippocampal atrophy.
- Understanding these changes is crucial for early diagnosis and intervention.
Purpose of the Study:
- To investigate the correlation between gray and white matter volumes and neuropsychological test performance in PD-MCI patients.
- To utilize volumetric magnetic resonance imaging (MRI) to assess brain structure in PD-MCI.
- To explore the relationship between neuroimaging findings and cognitive deficits.
Main Methods:
- A comparative study involving 26 PD-MCI patients and 26 healthy elderly controls (HC).
- Volumetric magnetic resonance imaging (MRI) was used to measure gray matter volume (GMV) and white matter volume (WMV).
- A battery of neuropsychological tests was administered to assess cognitive function.
Main Results:
- PD-MCI patients demonstrated impaired scores on several neuropsychological tests, including the Mini Mental State Examination, Trail Making Test Part A, Clock Drawing Test, Benton Line Judgment Orientation Test, and pentagon figure-copying.
- These cognitive deficits were associated with decreased brain volumes in PD-MCI patients.
- A more significant decline in White matter volume (WMV) was observed in PD-MCI patients compared to localized Gray matter volume (GMV) loss.
Conclusions:
- White matter volume reduction is a prominent feature in PD-MCI, potentially more so than localized gray matter loss.
- Impaired performance on specific neuropsychological tests in PD-MCI patients may serve as early indicators for the progression towards dementia.
- These findings highlight the potential of integrating neuroimaging and neuropsychological assessments for monitoring PD-MCI progression.
More Related Videos
Related Concept Videos
Parkinson's Disease: Overview
551
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
551
Parkinson's Disease: Treatment
272
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
272
Alzheimer's Disease: Overview
490
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
490
Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
Cognitive Development During Adulthood
112
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
112
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
126
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
126


